DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Response to Amendment
The amendment filed 06/01/2026 has been entered. Claims 1-12 remain pending in the
application.
Response to Arguments
Applicant’s arguments with respect to claim 1 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument.
Regarding the argument that “flap” in the prior art is only mentioned with components 52 and 53 and elements 111 and 112 are referenced by the term “connection tab,” the Examiner does not believe this is relevant. The limitation “flap” is being given its broadest reasonable interpretation to mean “something that is broad or flat and usually thin and flexible and that hangs loose or projects freely” (see Merriam Webster Online definition 1), which the connection tabs 11 and 112 can be considered to read upon. The statement that the “flap” is a part of the vascular prosthesis that is attached on one side of the intermediate potion, referencing the specification of the Instant Application, the Examiner contests that the flap of the prior art is connected to the intermediate portion (see rejection below).
Regarding the assertion about the first lumen not having the upstream and downstream end open to the outside, this is moot in view of the new interpretation of the first and second lumen in the new rejection that has been applied below.
Regarding the assertion that functional language should be given full patentable weight, the Examiner disagrees. The functional language is given patentable weight, however the weight that it is given it limited, as the prior art is not required to explicitly disclose exact functional language. Whilst functional language can provide context and help “bound the scope of the claim,” apparatus claims only require the apparatus of the prior art to be capable of the functional language.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-3 and 5-12 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by US 6033435 A (hereafter --Penn--).
Regarding Claim 1, Penn discloses a vascular prosthesis configured to be implanted in a vessel and allow blood flow therethrough, having substantially a T-shape (see annotated vascular prosthesis 100 in Figures 16 below), comprising a proximal tubular part forming the base of the "T" and a distal tubular part forming the head of the "T" (see annotated proximal tubular and distal tubular parts in Figure 16 below), wherein: the proximal tubular part has a first lumen, the distal tubular part has a second lumen and the first lumen and the second lumen are fluidly connected to form a common lumen (see annotated first and second lumens in Figure 16 below), wherein the first lumen has a downstream end open to the outside, and an upstream end connected to the second lumen, and wherein the second lumen has an upstream end and a downstream end, both open to the outside (see annotated downstream end and upstream end in Figure 16 below);
the distal tubular part comprises a first end portion at the upstream end of the second lumen (see annotated first end portion in Figure 16 below), a second end portion at the downstream end of the second lumen (see annotated second end portion in Figure 16 below), and an intermediate portion extending axially between the first end portion and second end portion, the intermediate portion being provided with a lateral window fluidly connected with the upstream end of the first lumen and from which the proximal tubular part extends (see annotated lateral window in Figure 15 below), the lateral window being surrounded by a peripheral frame (see annotated first end portion, second end portion, intermediate portion, lateral window, and peripheral frame in Figure 15 below); the first end portion and the intermediate portion are radially expandable (see Abstract);
the flap being opposed to a circumferential indentation of the second end portion in the unfolded position (see annotated circumferential indentation in Figures 16 below, the indentation being the top point of the annotated structure, the point directed towards the opposite direction that the flap extends from the second portion to, the limitation “indentation” being interpreted broadly, as meaning “an angular cut (such as a notch) or something resembling such a cut in an edge” (see Merriam Webster definition 2a), the point in the red circle in Figure 16 below being the “indentation”); the flap has a structural frame comprising an arched segment (see arched segment in Figures 15 and 16 below); and the arched segment is connected at its ends to the intermediate portion (see annotated intermediate portion and end in Figure 15 below, the other end being on the other side of the flap that is not visible in the Figure), on each side of the peripheral frame (see end connected to side of peripheral frame that is visible in the figure in Figure 16 below, the other side not visible the figure being the other of the “each side” of the peripheral frame), and surrounds a portion of the peripheral frame in the unfolded position (see end connected to side of peripheral frame that is visible in the figure in Figure 16 below, the other side not visible the figure being the other of the “each side” of the peripheral frame, the ends “surrounding” the portions of the peripheral frame that it is connected to).
PNG
media_image1.png
597
854
media_image1.png
Greyscale
The limitation “the second end portion is formed by a flap movable between a folded position in which the flap is folded inside the second lumen and an unfolded position in which the flap is axially deployed” is treated as functional language, that is not given full patentable weight. The prior art is not required to disclose this function, but merely have the capability of performing the recited function. Due to the specification disclosing that the flaps can be bent and that the stent is expandable (see Abstract, see column 4, lines 9-12 denoting that the stent can be expanded, see also column 12, lines 66- column 13 line 2 denoting that the flaps can be bent), the flaps are capable of being movable between a folded position in which the flap is folded inside the second lumen and an unfolded position in which the flap is axially deployed.
The limitation “the arched segment being bendable so as to form a joint for the folding/unfolding movement of the flap” is treated as functional language, that is not given full patentable weight. The prior art is not required to disclose this function, but merely have the capability of performing the recited function. Due to the specification disclosing that the flaps can be bent and that the stent is expandable, and the flaps being able to be bent at the arched segment (see annotated arched augment in Figure 15 below, see also Abstract, see column 4, lines 9-12 denoting that the stent can be expanded, see also column 12, lines 66- column 13 line 2 denoting that the flaps can be bent), the arched segment of the flaps are capable of being bendable so as to form a joint for the folding/unfolding movement of the flap.
PNG
media_image2.png
597
965
media_image2.png
Greyscale
Regarding Claim 2, Penn discloses the vascular prosthesis of claim 1.
The limitation “wherein the arched segment is elastically bendable between an unstable bent position corresponding to the folded position of the flap and a stable unbent position corresponding to the unfolded position of the flap” is treated as functional language, that is not given full patentable weight. The prior art is not required to disclose this function, but merely have the capability of performing the recited function. Due to the specification disclosing that the flaps can be bent and that the stent is expandable (see annotated arched augment in Figure 15 above, see also Abstract, see column 4, lines 9-12 denoting that the stent can be expanded, see also column 12, lines 66- column 13 line 2 denoting that the flaps can be bent), and the flaps being able to be bent at the arched segment (see annotated arched augment in Figure 15 above being bent and arched), the arched segment of the flaps are capable of being elastically bendable between an unstable bent position corresponding to the folded position of the flap and a stable unbent position corresponding to the unfolded position of the flap.
Regarding Claim 3, Penn discloses the vascular prosthesis of claim 1, wherein in the deployed position, the circumferential width of the flap decreases with the distance from the intermediate portion (see annotated flap in Figure 16 above, as the shape of the flap starts wider at the terminal outside ends that are on the first and second end portions, and get slimmer as the flap goes toward the “intermediate portion” (therefore the distance decreasing from the intermediate portion), see Figure 18 below showing the shape of the flap 111). The limitation “decreases with the distance from the intermediate portion” is being interpreted as, as the distance decreases from the intermediate portion (as the flap gets closer to the intermediate portion), the flap gets less wide across the circumference of the vascular device.
Regarding Claim 5, Penn discloses the vascular prosthesis of claim 1, wherein in the unfolded position, the flap is outwardly offset with respect to the axial direction of the distal tubular part (see annotated unfolded position and axis of the distal tubular part in Figure 16 above, “outward being towards the two ends of the tubular part facing the “outside”).
PNG
media_image3.png
313
629
media_image3.png
Greyscale
Regarding Claim 6, Penn discloses the vascular prosthesis of claim 1, wherein the structural frame of the flap further comprises at least one finger connected to the arched segment (see annotated finger in Figure 15 above, the finger connected to the arched portion as it is all interconnected).
Regarding Claim 7, Penn discloses the vascular prosthesis of claim 6, wherein the at least one finger extends from the middle of the arched segment (see annotated finger in Figure 15 below, the “middle” being the center along the long axis of the flap, the flap being shown in Figure 15 below).
Regarding Claim 8, Penn discloses the vascular prosthesis of claim 6, wherein the at least one finger extends perpendicularly from the arched segment (see annotated finger in Figure 15 below, the finger indirectly extending from the middle of the arched portion as it is all interconnected, the finger being perpendicular to the arched segment).
Regarding Claim 9, Penn discloses the vascular prosthesis of claim 6, wherein the at least one finger has a distal end with a hole (see annotated distal end and hole in Figure 20 below, see also column 13, lines 28-35).
PNG
media_image4.png
531
506
media_image4.png
Greyscale
Regarding Claim 10, Penn discloses the vascular prosthesis of claim 6, wherein the at least one finger has a distal end with a widening (see annotated finger in Figure 20 above). The limitation “widening” is being given its broadest reasonable interpretation, meaning “to increase the width, scope, or extent of”. Since the annotated distal end of the finger has a hole towards the inside end then is full and complete towards the outside end, it has widened as it has increased the extent of and scope of the material of the finger. Alternatively, the “distal end” of the finger would be the edge farthest from the flap (111/112). Since the claim doesn’t state what the “widening” is compared to, the long distal edge of the finger (117/118 as a whole) is wider than the short sides (see annotated short sides and “distal end” in Figure 20 below).
PNG
media_image5.png
541
393
media_image5.png
Greyscale
Regarding Claim 11, Penn discloses the vascular prosthesis of claim 6, wherein the at least one finger comprises at least one fold, so that, in the deployed position, the finger extends outwardly from the central axis of the distal tubular part (see annotated fold being the corner in the annotated box in Figure 20, see also finger in Figures 15 and 16 above extending outward from the center of the distal tubular part).
Regarding Claim 12, Penn discloses an implantation device comprising a vascular prosthesis according to claim 1 with the flap in the folded position (see column 4, line 61 to column 5, line 4 denoting the stent is in a contracted position), a sheath and a link between the sheath and the vascular prosthesis (see annotated sheath and implantation device in Figure 12 below, see also column 11, lines 18-25 denoting that sheaths have balloons within them that fill with air and press up against the inside of the vascular prosthesis, thereby “linking” the sheath and the prosthesis together since the balloon is attached to both components, see also column 11 line 65 to column 12 lines 1-2).
PNG
media_image6.png
336
481
media_image6.png
Greyscale
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claim 4 is rejected under 35 U.S.C. 103 as being unpatentable over US 6033435 A (hereafter --Penn--).
Regarding Claim 4, Penn discloses the vascular prosthesis of claim 1, in which the width of the flap in comparison to the lumen is clearly a small fraction of the second lumen circumference, as shown in Figures 15, 16, and 18 above).
Penn fails to disclose the specific size of the flaps in comparison with the size of the second lumen, specifically wherein the circumferential distance along the flap between the ends of the arched segment (see annotated ends of the arched segment) is comprised between 10% and 50% of the total circumference of the second lumen.
PNG
media_image7.png
331
521
media_image7.png
Greyscale
However, it would have been obvious to one of ordinary skill in the art before the effective filing date of the invention, since such a modification would have involved a mere change in the size of a component. A change in size is generally recognized as being within the level of ordinary skill in the art. In re Rose, 105 USPQ 237 (CCPA 1955).
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to PARIS MARIE BLASS whose telephone number is (703)756-5375. The examiner can normally be reached Monday - Thursday 9 a.m. - 7 p.m. ET.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melanie Tyson can be reached at 571-272-9062. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/PARIS MARIE BLASS/Examiner, Art Unit 3774
/SARAH W ALEMAN/Primary Examiner, Art Unit 3774